AltaRex Corp. Conference Call to Review Fiscal Year 1996 Results.EDMONTON, Alberta--(BUSINESS WIRE)--March 12, 1997--ALTAREX (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :AXO AXO Asianxo (website) AXO Alpha Chi Omega (sorority) AXO Ach So AXO Access Extension Object ) AltaRex Corp. will be holding a conference call on Friday, March 14, 1997 at 11:00 A.M. to review the Fiscal Year 1996 results which will be released at 4:00 P.M. on Thursday. Dr. Antoine A. Noujaim, President and C.E.O., Mr. Blaine Schamber, Vice President, Finance and Corporate Development, and Mr. Ron McMahan, Director, of AltaRex Corp. will deliver prepared remarks lasting approximately 20 minutes, to be followed by a question and answer period. To participate in the conference call from anywhere in North America, please call 1-800-390-5048 giving the operator your name and the name of the company hosting the conference call (AltaRex Corp.) at approximately 10:50 A.M. Eastern Time or at any time during the conference call. For those unable to participate, a recording of the call will be available 1 hour following its completion. To listen to this tape you can call 1-800-408-3053, password 106295. AltaRex Corp. is an Alberta based, biopharmaceutical company which focuses on the discovery and development of products providing an integrated approach to the treatment and diagnosis of cancer. AltaRex Corp.'s lead therapeutic cancer product OVAREX(TM) therapeutic vaccine therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. is currently in Phase II/III clinical trials in Canada and Europe for treatment of advanced ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast . The company anticipates commencing an OVAREX(TM) Phase II/III clinical trial in the United States in the second quarter of this year. AltaRex also has products for the treatment of breast and colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. at the pre-clinical development stage and is developing Treosulfan(R), a relatively non-toxic chemotherapeutic agent chemotherapeutic agent An agent used to treat CA, administered in 'regimens'-one or more 'cycles' that combine 3 or more agents over wks; CAs are toxic to any cell with a high rate of proliferation–the CA itself, the GI tract–causing N&V, . CONTACT: Altarex Corp. Blaine Schamber, 403/ 492-3920 403/ 492-8999 (FAX) altarex@planet.eon.net |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion